Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
about
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsState of the Art, Unresolved Issues, and Future Research Directions in the Fight against Hepatitis C Virus: Perspectives for Screening, Diagnostics of Resistances, and ImmunizationModeling viral evolutionary dynamics after telaprevir-based treatmentGeno2pheno[HCV] - A Web-based Interpretation System to Support Hepatitis C Treatment Decisions in the Era of Direct-Acting Antiviral AgentsHigh-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methodsNaturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China.Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance.Hepatitis C virus NS5A inhibitors and drug resistance mutations.All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.Ledipasvir/Sofosbuvir.Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.Hepatitis C virus infection: Are there still specific problems with genotype 3?Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naïve patients.Characterization of Naturally Occurring NS5A and NS5B Polymorphisms in Patients Infected with HCV Genotype 3a Treated with Direct-Acting Antiviral Agents.Genotype 3 Infection: The Last Stand of Hepatitis C Virus.Prevention and management of treatment failure to new oral hepatitis C drugs.Prevalence of polymorphisms with significant resistance to NS5A inhibitors in treatment-naive patients with hepatitis C virus genotypes 1a and 3a in Sweden.Detection of a genetic footprint of the sofosbuvir resistance-associated substitution S282T after HCV treatment failure.Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS5A Inhibitor Pibrentasvir.Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens.Manipulation of both virus- and cell-specific factors is required for robust transient replication of a hepatitis C virus genotype 3a sub-genomic replicon.Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.Naturally Occurring Resistance-Associated Variants to Hepatitis C Virus Direct-Acting Antiviral Agents in Treatment-Naive HCV Genotype 6a-Infected Patients.Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.In Vitro Antiviral Activity and Resistance Profile of the Next-Generation Hepatitis C Virus NS3/4A Protease Inhibitor Glecaprevir.The global origins of resistance-associated variants in the non-structural proteins 5A and 5B of the hepatitis C virus.Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 InfectionPooled Resistance Analysis in Patients with Hepatitis C Virus Genotype 1 to 6 Infection Treated with Glecaprevir-Pibrentasvir in Phase 2 and 3 Clinical Trials
P2860
Q26777408-0919172E-2C44-429A-A79A-C656D569820AQ28079102-9AE02A4C-1557-4347-9C53-E1B7DBE32282Q28542375-6C608DF6-84C3-4865-B172-3E883921C711Q28552269-C12D87DA-6307-4C4C-B924-76873F7D7203Q28652352-6D9BF22C-F6BE-46E5-8408-BD96DE488C66Q33672648-924ED1C2-7C13-41B8-B154-C226ACDDF1FEQ34332546-CB0C0920-5BA3-42B7-813C-D2C093957132Q34411617-BE36EBF0-EB4E-4B18-A102-5E82C2C10F65Q35538245-2BCE3FBA-69B5-48C4-8B45-2276082B23BEQ36052231-E4E8A735-238C-4842-B48D-A81341E6E3A4Q36158391-322859CA-1604-4BDE-85D4-0F86B24563AFQ36269670-E1390953-C243-48FE-9316-5B6DB1AEA473Q37426527-2ABDD6D6-A929-4E1F-858F-E12BFD2042FFQ38637199-4985FA63-C064-4DD4-A39A-80E4CABEBE73Q38772047-C2881C35-FC26-47C6-BE7E-ADA64056319BQ38826624-3366AF76-EB92-4B60-8C01-9B72FFAC9C82Q39020651-22AB39D2-D813-46C0-9FEE-BB6629DF43A6Q40167095-88F916A3-73E0-41DD-A26E-59C84F479E45Q40189279-E7288C8E-AA05-4D53-B9B2-E1E9C20982AEQ40337619-C68EF134-1197-42F3-930D-313CED6D1F6BQ40416472-D97DF5D8-8701-45B2-AED9-30550CB85932Q40548267-A82F52E9-7877-407B-B65E-065541DB3A21Q41923026-5C45B053-3009-43D9-91B7-FE6DADEC5C0FQ41934673-EE18F51E-4EF0-4836-BB9F-9A72CBB047FEQ44104489-019B6681-DD01-4082-8BFB-016448BF3146Q45324912-72AEF1BD-C15A-4A8B-94D4-C006086F51E7Q45325504-B120DB83-9950-44B3-8EA1-2B09CC4115CEQ47549498-B101347E-184B-4A27-98B6-D5434D46E58AQ58697287-944B31C7-F7AD-4239-8C5C-F96B36E80074Q58701132-51261BDA-E247-4B78-B48C-8BC7ADD9EACA
P2860
Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Natural prevalence of NS5A pol ...... l activity of NS5A inhibitors.
@en
Natural prevalence of NS5A pol ...... l activity of NS5A inhibitors.
@nl
type
label
Natural prevalence of NS5A pol ...... l activity of NS5A inhibitors.
@en
Natural prevalence of NS5A pol ...... l activity of NS5A inhibitors.
@nl
prefLabel
Natural prevalence of NS5A pol ...... l activity of NS5A inhibitors.
@en
Natural prevalence of NS5A pol ...... l activity of NS5A inhibitors.
@nl
P2093
P1476
Natural prevalence of NS5A pol ...... l activity of NS5A inhibitors.
@en
P2093
Aaron Monikowski
Dennis Hernandez
Fiona McPhee
Joseph Ueland
Nannan Zhou
P356
10.1016/J.JCV.2012.12.020
P577
2013-02-04T00:00:00Z